vs
null（SWIM）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是null的1.4倍（$140.6M vs $100.0M），VERACYTE, INC.净利率更高（29.3% vs -7.0%，领先36.3%），VERACYTE, INC.同比增速更快（18.5% vs 14.5%），VERACYTE, INC.自由现金流更多（$48.8M vs $14.1M），过去两年VERACYTE, INC.的营收复合增速更高（20.5% vs -4.9%）
该企业是一家源自美国的跨国律师事务所，1934年创立于加利福尼亚州洛杉矶，在诉讼业务、公司法务以及监管合规法律领域拥有深厚的行业积累与知名度，是全球颇具影响力的综合性律所之一。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
SWIM vs VCYT — 直观对比
营收规模更大
VCYT
是对方的1.4倍
$100.0M
营收增速更快
VCYT
高出4.0%
14.5%
净利率更高
VCYT
高出36.3%
-7.0%
自由现金流更多
VCYT
多$34.7M
$14.1M
两年增速更快
VCYT
近两年复合增速
-4.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $100.0M | $140.6M |
| 净利润 | $-7.0M | $41.1M |
| 毛利率 | 28.0% | 72.5% |
| 营业利润率 | -10.7% | 26.4% |
| 净利率 | -7.0% | 29.3% |
| 营收同比 | 14.5% | 18.5% |
| 净利润同比 | 76.0% | 704.8% |
| 每股收益（稀释后） | $-0.06 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SWIMVCYT
| Q4 25 | $100.0M | $140.6M | ||
| Q3 25 | $161.9M | $131.9M | ||
| Q2 25 | $172.6M | $130.2M | ||
| Q1 25 | $111.4M | $114.5M | ||
| Q4 24 | $87.3M | $118.6M | ||
| Q3 24 | $150.5M | $115.9M | ||
| Q2 24 | $160.1M | $114.4M | ||
| Q1 24 | $110.6M | $96.8M |
净利润SWIMVCYT
| Q4 25 | $-7.0M | $41.1M | ||
| Q3 25 | $8.1M | $19.1M | ||
| Q2 25 | $16.0M | $-980.0K | ||
| Q1 25 | $-6.0M | $7.0M | ||
| Q4 24 | $-29.2M | $5.1M | ||
| Q3 24 | $5.9M | $15.2M | ||
| Q2 24 | $13.3M | $5.7M | ||
| Q1 24 | $-7.9M | $-1.9M |
毛利率SWIMVCYT
| Q4 25 | 28.0% | 72.5% | ||
| Q3 25 | 35.4% | 69.2% | ||
| Q2 25 | 37.1% | 69.0% | ||
| Q1 25 | 29.5% | 69.5% | ||
| Q4 24 | 24.6% | 66.4% | ||
| Q3 24 | 32.4% | 68.2% | ||
| Q2 24 | 33.1% | 68.1% | ||
| Q1 24 | 27.7% | 64.5% |
营业利润率SWIMVCYT
| Q4 25 | -10.7% | 26.4% | ||
| Q3 25 | 13.3% | 17.4% | ||
| Q2 25 | 14.3% | -4.0% | ||
| Q1 25 | -4.4% | 2.5% | ||
| Q4 24 | -14.9% | 3.5% | ||
| Q3 24 | 8.9% | 10.4% | ||
| Q2 24 | 12.5% | 4.0% | ||
| Q1 24 | -1.9% | -4.8% |
净利率SWIMVCYT
| Q4 25 | -7.0% | 29.3% | ||
| Q3 25 | 5.0% | 14.5% | ||
| Q2 25 | 9.3% | -0.8% | ||
| Q1 25 | -5.4% | 6.2% | ||
| Q4 24 | -33.4% | 4.3% | ||
| Q3 24 | 3.9% | 13.1% | ||
| Q2 24 | 8.3% | 5.0% | ||
| Q1 24 | -7.1% | -1.9% |
每股收益（稀释后）SWIMVCYT
| Q4 25 | $-0.06 | $0.50 | ||
| Q3 25 | $0.07 | $0.24 | ||
| Q2 25 | $0.13 | $-0.01 | ||
| Q1 25 | $-0.05 | $0.09 | ||
| Q4 24 | $-0.24 | $0.07 | ||
| Q3 24 | $0.05 | $0.19 | ||
| Q2 24 | $0.11 | $0.07 | ||
| Q1 24 | $-0.07 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $362.6M |
| 总债务越低越好 | $279.8M | — |
| 股东权益账面价值 | $405.9M | $1.3B |
| 总资产 | $823.2M | $1.4B |
| 负债/权益比越低杠杆越低 | 0.69× | — |
8季度趋势，按日历期对齐
现金及短期投资SWIMVCYT
| Q4 25 | — | $362.6M | ||
| Q3 25 | — | $315.6M | ||
| Q2 25 | — | $219.5M | ||
| Q1 25 | — | $186.1M | ||
| Q4 24 | — | $239.1M | ||
| Q3 24 | — | $274.1M | ||
| Q2 24 | — | $235.9M | ||
| Q1 24 | — | $209.2M |
总债务SWIMVCYT
| Q4 25 | $279.8M | — | ||
| Q3 25 | $281.1M | — | ||
| Q2 25 | $281.5M | — | ||
| Q1 25 | $306.9M | — | ||
| Q4 24 | $281.5M | — | ||
| Q3 24 | $282.8M | — | ||
| Q2 24 | $282.4M | — | ||
| Q1 24 | $282.8M | — |
股东权益SWIMVCYT
| Q4 25 | $405.9M | $1.3B | ||
| Q3 25 | $408.4M | $1.3B | ||
| Q2 25 | $398.4M | $1.2B | ||
| Q1 25 | $381.1M | $1.2B | ||
| Q4 24 | $387.2M | $1.2B | ||
| Q3 24 | $416.6M | $1.2B | ||
| Q2 24 | $408.1M | $1.1B | ||
| Q1 24 | $391.8M | $1.1B |
总资产SWIMVCYT
| Q4 25 | $823.2M | $1.4B | ||
| Q3 25 | $844.4M | $1.4B | ||
| Q2 25 | $822.1M | $1.3B | ||
| Q1 25 | $824.6M | $1.3B | ||
| Q4 24 | $794.2M | $1.3B | ||
| Q3 24 | $853.4M | $1.3B | ||
| Q2 24 | $830.0M | $1.2B | ||
| Q1 24 | $808.6M | $1.2B |
负债/权益比SWIMVCYT
| Q4 25 | 0.69× | — | ||
| Q3 25 | 0.69× | — | ||
| Q2 25 | 0.71× | — | ||
| Q1 25 | 0.81× | — | ||
| Q4 24 | 0.73× | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.69× | — | ||
| Q1 24 | 0.72× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $23.3M | $52.6M |
| 自由现金流经营现金流 - 资本支出 | $14.1M | $48.8M |
| 自由现金流率自由现金流/营收 | 14.1% | 34.7% |
| 资本支出强度资本支出/营收 | 9.2% | 2.7% |
| 现金转化率经营现金流/净利润 | — | 1.28× |
| 过去12个月自由现金流最近4个季度 | $38.0M | $126.6M |
8季度趋势，按日历期对齐
经营现金流SWIMVCYT
| Q4 25 | $23.3M | $52.6M | ||
| Q3 25 | $51.0M | $44.8M | ||
| Q2 25 | $36.0M | $33.6M | ||
| Q1 25 | $-46.9M | $5.4M | ||
| Q4 24 | $6.2M | $24.5M | ||
| Q3 24 | $37.2M | $30.0M | ||
| Q2 24 | $52.4M | $29.6M | ||
| Q1 24 | $-34.5M | $-9.0M |
自由现金流SWIMVCYT
| Q4 25 | $14.1M | $48.8M | ||
| Q3 25 | $45.2M | $42.0M | ||
| Q2 25 | $29.1M | $32.3M | ||
| Q1 25 | $-50.3M | $3.5M | ||
| Q4 24 | $-98.0K | $20.4M | ||
| Q3 24 | $33.2M | $27.7M | ||
| Q2 24 | $47.9M | $26.8M | ||
| Q1 24 | $-39.9M | $-11.1M |
自由现金流率SWIMVCYT
| Q4 25 | 14.1% | 34.7% | ||
| Q3 25 | 27.9% | 31.8% | ||
| Q2 25 | 16.8% | 24.8% | ||
| Q1 25 | -45.2% | 3.1% | ||
| Q4 24 | -0.1% | 17.2% | ||
| Q3 24 | 22.1% | 23.9% | ||
| Q2 24 | 29.9% | 23.4% | ||
| Q1 24 | -36.0% | -11.5% |
资本支出强度SWIMVCYT
| Q4 25 | 9.2% | 2.7% | ||
| Q3 25 | 3.6% | 2.1% | ||
| Q2 25 | 4.0% | 1.0% | ||
| Q1 25 | 3.1% | 1.6% | ||
| Q4 24 | 7.2% | 3.5% | ||
| Q3 24 | 2.7% | 1.9% | ||
| Q2 24 | 2.8% | 2.4% | ||
| Q1 24 | 4.8% | 2.2% |
现金转化率SWIMVCYT
| Q4 25 | — | 1.28× | ||
| Q3 25 | 6.29× | 2.34× | ||
| Q2 25 | 2.25× | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | 6.32× | 1.98× | ||
| Q2 24 | 3.95× | 5.16× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SWIM
| In Ground Swimming Pools | $50.2M | 50% |
| Covers | $37.0M | 37% |
| Liners | $12.7M | 13% |
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
